Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Complicated Skin And Skin Structure Infections (cSSSI)-Pipeline Review, H1 2015

Complicated Skin And Skin Structure Infections (cSSSI)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Complicated Skin And Skin Structure Infections (cSSSI)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Complicated Skin And Skin Structure Infections (cSSSI)-Pipeline Review, H1 2015', provides an overview of the Complicated Skin And Skin Structure Infections (cSSSI)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Complicated Skin And Skin Structure Infections (cSSSI), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Complicated Skin And Skin Structure Infections (cSSSI) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Complicated Skin And Skin Structure Infections (cSSSI)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Complicated Skin And Skin Structure Infections (cSSSI) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Complicated Skin And Skin Structure Infections (cSSSI) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Complicated Skin And Skin Structure Infections (cSSSI) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Complicated Skin And Skin Structure Infections (cSSSI)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Complicated Skin And Skin Structure Infections (cSSSI) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Complicated Skin And Skin Structure Infections (cSSSI) Overview 7

Therapeutics Development 8

Pipeline Products for Complicated Skin And Skin Structure Infections (cSSSI)-Overview 8

Pipeline Products for Complicated Skin And Skin Structure Infections (cSSSI)-Comparative Analysis 9

Complicated Skin And Skin Structure Infections (cSSSI)-Therapeutics under Development by Companies 10

Complicated Skin And Skin Structure Infections (cSSSI)-Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Complicated Skin And Skin Structure Infections (cSSSI)-Products under Development by Companies 14

Complicated Skin And Skin Structure Infections (cSSSI)-Companies Involved in Therapeutics Development 15

Cempra, Inc. 15

CrystalGenomics, Inc. 16

Debiopharm International S.A. 17

Dong-A Socio Group 18

GlaxoSmithKline plc 19

Melinta Therapeutics, Inc 20

Phosphagenics Limited 21

Complicated Skin And Skin Structure Infections (cSSSI)-Therapeutics Assessment 22

Assessment by Monotherapy Products 22

Assessment by Target 23

Assessment by Mechanism of Action 25

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Drug Profiles 30

CG-400549-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Debio-1450-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Debio-1452-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

delafloxacin-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

fusidic acid-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

GSK-2140944-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

iclaprim mesylate-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

lanopepden-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

Small Molecule for Skin Infections-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Small Molecules to Inhibit DHFR for Infectious Diseases-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

tedizolid phosphate-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Complicated Skin And Skin Structure Infections (cSSSI)-Recent Pipeline Updates 51

Complicated Skin And Skin Structure Infections (cSSSI)-Dormant Projects 67

Complicated Skin And Skin Structure Infections (cSSSI)-Product Development Milestones 68

Featured News & Press Releases 68

Apr 30, 2014: Cubist to Present New Pipeline Data Of Tedizolid Phosphate At 2014 European Congress of Clinical Microbiology and Infectious Diseases 68

Oct 22, 2013: Cubist Announces Submission of New Drug Application for Investigational Antibiotic Tedizolid for Treatment of Serious Skin Infections 68

Sep 04, 2013: Affinium Pharmaceuticals Announces the Initiation of a Phase 1 Intravenous Clinical Trial of a New Antibiotic Prodrug 69

Appendix 71

Methodology 71

Coverage 71

Secondary Research 71

Primary Research 71

Expert Panel Validation 71

Contact Us 71

Disclaimer 72

List of Tables

Number of Products under Development for Complicated Skin And Skin Structure Infections (cSSSI), H1 2015 8

Number of Products under Development for Complicated Skin And Skin Structure Infections (cSSSI)-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Late Stage Development, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 12

Comparative Analysis by Early Stage Development, H1 2015 13

Products under Development by Companies, H1 2015 14

Complicated Skin And Skin Structure Infections (cSSSI)-Pipeline by Cempra, Inc., H1 2015 15

Complicated Skin And Skin Structure Infections (cSSSI)-Pipeline by CrystalGenomics, Inc., H1 2015 16

Complicated Skin And Skin Structure Infections (cSSSI)-Pipeline by Debiopharm International S.A., H1 2015 17

Complicated Skin And Skin Structure Infections (cSSSI)-Pipeline by Dong-A Socio Group, H1 2015 18

Complicated Skin And Skin Structure Infections (cSSSI)-Pipeline by GlaxoSmithKline plc, H1 2015 19

Complicated Skin And Skin Structure Infections (cSSSI)-Pipeline by Melinta Therapeutics, Inc, H1 2015 20

Complicated Skin And Skin Structure Infections (cSSSI)-Pipeline by Phosphagenics Limited, H1 2015 21

Assessment by Monotherapy Products, H1 2015 22

Number of Products by Stage and Target, H1 2015 24

Number of Products by Stage and Mechanism of Action, H1 2015 26

Number of Products by Stage and Route of Administration, H1 2015 28

Number of Products by Stage and Molecule Type, H1 2015 29

Complicated Skin And Skin Structure Infections (cSSSI) Therapeutics-Recent Pipeline Updates, H1 2015 51

Complicated Skin And Skin Structure Infections (cSSSI)-Dormant Projects, H1 2015 67

List of Figures

Number of Products under Development for Complicated Skin And Skin Structure Infections (cSSSI), H1 2015 8

Number of Products under Development for Complicated Skin And Skin Structure Infections (cSSSI)-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Late Stage Development, H1 2015 11

Comparative Analysis by Early Stage Products, H1 2015 13

Assessment by Monotherapy Products, H1 2015 22

Number of Products by Top 10 Targets, H1 2015 23

Number of Products by Stage and Top 10 Targets, H1 2015 24

Number of Products by Top 10 Mechanism of Actions, H1 2015 25

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 26

Number of Products by Top 10 Routes of Administration, H1 2015 27

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 28

Number of Products by Stage and Top 10 Molecule Types, H1 2015 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Cempra, Inc.

CrystalGenomics, Inc.

Debiopharm International S.A.

Dong-A Socio Group

GlaxoSmithKline plc

Melinta Therapeutics, Inc

Phosphagenics Limited

Complicated Skin And Skin Structure Infections (cSSSI) Therapeutic Products under Development, Key Players in Complicated Skin And Skin Structure Infections (cSSSI) Therapeutics, Complicated Skin And Skin Structure Infections (cSSSI) Pipeline Overview, Complicated Skin And Skin Structure Infections (cSSSI) Pipeline, Complicated Skin And Skin Structure Infections (cSSSI) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com